Niflumic acid

Discontinued Product

Niflumic acid (Cat. No. 4112) has been withdrawn from sale for commercial reasons.
Description: Cyclooxygenase-2 (COX-2) inhibitor; GPR35 agonist
Chemical Name: 2-[3-(Trifluoromethyl)anilino]nicotinic acid
Citations (5)
Reviews (1)
Literature (2)

Biological Activity for Niflumic acid

Niflumic acid is a nonsteroidal anti-inflammatory drug (NSAID); selectively inhibits COX-2. Also activates human TRPA1 inducibly expressed in HEK293 cells; displays agonist activity at GPR35.

Technical Data for Niflumic acid

M. Wt 282.22
Formula C13H9F3N2O2
Storage Store at RT
CAS Number 4394-00-7
PubChem ID 4488
Smiles O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Niflumic acid

References for Niflumic acid

References are publications that support the biological activity of the product.

Ottolia and Toro (1994) Potentiation of large conductance KCa channels by niflumic, flufenamic and mefenamic acids. Biophys.J. 67 2272 PMID: 7535111

Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437 PMID: 9427063

Hu et al (2010) Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch. 459 579 PMID: 19888597

Deng et al (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci.Rep. 2 373 PMID: 22523636

View Related Products by Target

View Related Products by Product Action

View all Cyclooxygenase Inhibitors

Keywords: Niflumic acid, Niflumic acid supplier, cyclooxygenase, 2, cox-2, inhibitors, inhibits, Cyclooxygenase, GPR35, 4112, Tocris Bioscience

5 Citations for Niflumic acid

Citations are publications that use Tocris products. Selected citations for Niflumic acid include:

Rayner et al (2019) Mechanism and effects of pulsatile GABA secretion from cytosolic pools in the human beta cell. Nat Metab 1 1110-1126 PMID: 32432213

Ute et al (2022) Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers. Exp Dermatol 31 1477-1499 PMID: 35913427

Cao et al (2014) SLC17A9 protein functions as a lysosomal ATP transporter and regulates cell viability. J Neuroinflammation 289 23189 PMID: 24962569

Xi et al (2020) Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. J Exp Med 217 PMID: 32097463

Reviews for Niflumic acid

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Niflumic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Niflumic acid increases non-selective cationic current in cardiomyocytes.
By Chintan Koyani on 10/23/2018
Assay Type: In Vitro
Species: Other
Cell Line/Tissue: Cardiomyocytes

Non-selective cationic current was measured in guinea pig cardiomyocytes before and after superfusion with 100 µM niflumic acid for 10 min. Compared to time matched rundown, niflumic acid significantly increased inward as well as outward non-selective cationic current in cardiomyocytes.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.